GSK Agrees to $357 Million Exclusive License Agreement
GSK secures exclusive rights to Syndivia's promising ADC for metastatic castration-resistant prostate cancer, enhancing treatment options for patients.
GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in development for the treatment of Metastatic castration-resistant prostate cancer (mCRPC).
Sasha Koniev, chief executive officer at Syndivia, said, “We are proud that GSK will advance this program on a global scale. This agreement underscores the value of our GeminiMab ADC platform and the opportunity to bring a promising new therapy to patients with pressing unmet medical needs.
The agreement grants GSK the exclusive rights to the development and commercialization of the ADC worldwide.
Author's summary: GSK acquires exclusive rights to Syndivia's ADC.
More News
- Trump Admin’s Laziness Is Messing Up Its Effort to Deploy the National Guard to Portland
- FG backs Dangote Refinery’s expansion to 1.4m barrels daily — Lokpobiri
- Pharmaceutical Executive Daily: New Research Suggests Ozempic May Reduce Biological Age | PharmExec
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Lightning place forward Mitchell Chaffee on waivers
- Court: Federal Agencies Broke Laws in Approving Massive Logging Project in Montana Grizzly Country
- What is canine cognitive dysfunction syndrome? | dvm360
- Brad Sutton on Boston Scientific's PFA advantage and advice for medtech pros